{
  "pmcid": "12424048",
  "sha256": "0133718dbdbb19a007bdc67814471a2488f87218b8ecddb91f3c4650e086a60e",
  "timestamp_utc": "2025-11-09T22:25:59.371038+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 17.732842415316643,
    "reading_ease": -7.3918556701030695,
    "word_count": 194
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Intraoperative Molecular Imaging with Pafolacianine in Pulmonary Resection"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "In a multicenter, randomised phase 3 trial (ELUCIDATE; NCT04241315), 100 participants undergoing pulmonary resection were randomised"
      },
      "Participants": {
        "score": 2,
        "evidence": "Eligibility criteria included patients with suspected lung cancer, confirmed by preoperative CT with 1.25-mm slices."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants received 0.025 mg/kg of pafolacianine intravenously 1 to 24 hours before surgery."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates the efficacy of intraoperative molecular imaging (IMI) with pafolacianine in identifying occult pulmonary lesions"
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "The primary outcome was the identification of occult lesions, measured intraoperatively."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "100 participants were randomised to the intervention group."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "IMI identified 29 occult lesions in 23 participants (23%). Of these, 10 lesions (34%) were malignant."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were minimal, with no significant perioperative morbidity reported."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "The trial was registered under NCT04241315"
      },
      "Funding": {
        "score": 1,
        "evidence": "funded by Medidata Solutions"
      }
    },
    "total_score": 14,
    "max_score": 25
  }
}